The effect of GM-CSF (Granulocyte Macrophage Colony Stimulating Factor) on doxorubicin induced tissue necrosis and wound healing

Indian Journal of Cancer

Volumn 37, Issue 4, 2000, Pages 153-157

  Eroglu, E ^a   Sari, A ^a   Altuntas, I ^a   Delibas, N ^a   Candir, O ^a   Agalar, F ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYPROLINE;

ANIMAL; ARTICLE; COMPARATIVE STUDY; DRUG EFFECT; EOSINOPHIL; FIBROBLAST; LYMPHOCYTE; MALE; METABOLISM; NECROSIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RAT; SKIN; SKIN ULCER; WISTAR RAT; WOUND HEALING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; EOSINOPHILS; FIBROBLASTS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HYDROXYPROLINE; LYMPHOCYTES; MALE; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, WISTAR; SKIN; SKIN ULCER; WOUND HEALING;

EID: 0034584938     PISSN: 0019509X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Lebredo L., Barrie R., Woltering E.A. : DMSO protects against adriamycin-induced tissue necrosis. J. Surg Res 1992:53;62-65.
2. Cox R.F. : Managing skin damage induced by doxorubicin hydrochloride and doxorubicin hydrochloride. Am J Hosp Pharm 1984:41;2410-4.
3. Harwood K.V., Bachur N. : Evaluation of dimethyl sulfoxide and local cooling as antidotes for doxorubicin extravasation in a pig model. Oncol Nurs Forum 1987:14;39-44.
4. Olver I.N., Aisner J., Hament A., et al. : A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 1988:6;1732-5.
5. Dorr R.T.: Antidotes to vesicant chemotherapy extravasations. Blood Rev 1990:4;41-60.
6. Tarr P.E. : Granulocyte-macrophage colony-stimulating factor and the immune system. Med Oncol 1996:13;133-40.
7. Jyung R.W., Wu L., Pierce G.F., et al.: Granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor : differential action on incisional wound healing. Surgery 1994;115:325-34.
8. Grzybowski J., Oldak E., Janiak M.K.: Local application of G-CSF, GM-CSF and EGF in treatment of wounds. Postepy Hig Med Dosw 1999:53;75-86.
9. Woessner J.B. : The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Archives of Biochemistry and Biophysics 1961:93;440-47.
10. Dorr R.T., Alberts D.S. : Failure of DMSO and vitamin E to prevent doxorubicin skin ulceration in the mouse. Cancer Treat Rep 1983:67;499-501.
11. Hajarizadeh H., Lebredo L., Barrie R., et al .: Proctective effect of doxorubicin in vitamin C or dimethyl sulfoxide against skin ulceration in the pig. Ann Surg Oncol 1994:1;411-4.
12. Bertelli G., Gozza A., Forno G.B., et al : Topical dimethyl sulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs. A prospective clinical study. J Clin Oncol 1995:13;2851-5.
13. Bertelli G., Dini D., Forno G.B., et al. : Clinical results with antidotes to vesicant chemotherapy extravasations. Proc Annu Meet Am Soc Clin Oncol (abstr) 1994:13;A11627.
14. Upton P.G., Yamaguchi K.T., Myers S., et al.: Effects of antioxidants and hyperbaric oxygen in ameliorating experimental doxorubicin skin toxicity in the rat. Cancer Treat Rep 1986:70;503-7.
15. Averbuch S.D., Gaudiano G., Koch T.H., et al.: Doxorubicin induced skin necrosis in the swine model : protection with a novel radical dimer. J Clin Oncol 1986:4;88-94.
16. Dorr R.T., Alberts D.S. : Modulation of experimental doxorubicin skin toxicity by beta-adrenergic compounds. Cancer Res 1981:41;2428-2432.
17. Dorr R.T., Alberts D.S., Chen H.G.: Experimental model of doxorubicin extravasation in the mouse. J Pharmacol Methods 1980:4;237-250.
18. Barthowski-Dodds L., Daniels J.R. : Use of sodium bicarbonate as a means of ameliorating doxorubicin induced dermal necrosis in rats. Cancer Chemother Pharmacol 1980:4;179-181.
19. Vasilev S.A., Morrow C., Morrow C.P. : Basic fibroblast growth factor in retardatoin of doxorubicin extravasation injury. Gynecol Oncol 1992:44;178-81.
20. Buhring M., Menzel I. : Tissue damage after paravenous application of cytostic agents : an additional treatment with transcutaneous electric nerve stimulation. Onkologie 1982:5;280-283.
21. Preuss P., Partoft S. : Cytostatic extravasations. Ann Plast Surg 1987: 19;323-9.
22. Loth T.S., Eversmann W.W. Jr : Treatment methods for extravasations of chemotherapeutic agents : a comparative study. J Hand Surg 19861:1;388-96.
23. Loth T.S.: Minimal surgical debridement for the treatment of chemotherapeutic agents induced skin extravasations. Cancer Treat Rep 1986:70;401-4.
24. Mamakos M.S. : Recall phenomenon or severe skin and muscle necrosis following adriamycin extravasation in the hand. Int Surg 1984:69;73-4.
25. Dahlstrm K.K., Chenoufi H.L., Daugaard S.: Flourescence microscopic demostration and demarcation of doxorubicin extravasation. Experimental and clinical studies. Cancer 1990:65;1722-6.
26. Peters W.P., Stuart A., Affronti M.L., et al.: Neutrophil migration is defective during recombinant human granulocyte macrophage colony stimulating factor infusion after autologous bone marrow trasplantation in humans. Blood 1988:72;1310-1315.
27. Rannistra S., Socinski M.A., Groshek P., et al.: Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances monocyte tumoricidal activity.Proc Am Soc Clin Oncol (abstr) 1988:7;645.
28. Wing E.J., Magee D.M., Kaplan S.S., et al : Stimulation of human monocytes by recombinant granulocyte-macrophage colony stimulating factor in patients with metastic carcinoma. Clin Res 1988:36;422.
29. Shamseddire A.I., Khalil A.M., Kibbi A.G., et al.: Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) for treatment of chemotherapy extravasation. Eur J Gynaecol Oncol 1998:19;479-81.